{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-09-01T05:16:39.136776+00:00","company":{"ticker":"XTNT","cik":1453593,"company_name":"Xtant Medical Holdings, Inc."},"pagination":{"limit":100,"returned":59,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Surgalign Holdings, Inc.","detail":"asset_purchase","count":2,"first_seen":"2023-06-20T23:59:59+00:00","last_seen":"2023-07-11T23:59:59+00:00","evidence_fact_ids":[132576,137065]},{"display_name":"Craig-Hallum Capital Group LLC","detail":"underwriting","count":1,"first_seen":"2023-07-03T23:59:59+00:00","last_seen":"2023-07-03T23:59:59+00:00","evidence_fact_ids":[133861]},{"display_name":"MidCap Financial Trust","detail":"credit_facility","count":1,"first_seen":"2023-08-10T23:59:59+00:00","last_seen":"2023-08-10T23:59:59+00:00","evidence_fact_ids":[120465]},{"display_name":"MidCap Financial Trust and MidCap Funding IV Trust","detail":"credit_facility","count":1,"first_seen":"2024-03-07T23:59:59+00:00","last_seen":"2024-03-07T23:59:59+00:00","evidence_fact_ids":[69004]},{"display_name":"MidCap Financial Trust and the financial institutions party thereto","detail":"credit_facility","count":1,"first_seen":"2023-03-01T23:59:59+00:00","last_seen":"2023-03-01T23:59:59+00:00","evidence_fact_ids":[174844]},{"display_name":"MidCap Funding IV Trust and the financial institutions party thereto","detail":"credit_facility","count":1,"first_seen":"2023-03-01T23:59:59+00:00","last_seen":"2023-03-01T23:59:59+00:00","evidence_fact_ids":[174845]},{"display_name":"Surgalign SPV, Inc. and Seller","detail":"other","count":1,"first_seen":"2023-03-01T23:59:59+00:00","last_seen":"2023-03-01T23:59:59+00:00","evidence_fact_ids":[174843]},{"display_name":"Surgalign SPV, Inc., Surgalign Spine Technologies, Inc., and Surgalign Holdings, Inc.","detail":"asset_purchase","count":1,"first_seen":"2023-03-01T23:59:59+00:00","last_seen":"2023-03-01T23:59:59+00:00","evidence_fact_ids":[174842]}],"lender":[{"display_name":"MidCap Financial Trust","detail":"credit_facility","count":3,"first_seen":"2023-03-01T23:59:59+00:00","last_seen":"2025-12-03T23:59:59+00:00","evidence_fact_ids":[37239,69006,174846]},{"display_name":"MidCap Funding IV Trust","detail":"revolving_credit","count":1,"first_seen":"2024-03-07T23:59:59+00:00","last_seen":"2024-03-07T23:59:59+00:00","evidence_fact_ids":[69007]}],"ma_counterparty":[{"display_name":"Companion Spine SAS","detail":"disposition","count":1,"first_seen":"2025-12-03T23:59:59+00:00","last_seen":"2025-12-03T23:59:59+00:00","evidence_fact_ids":[26107]},{"display_name":"Companion Spine, LLC and one of its affiliates, Companion Spine SAS","detail":"disposition","count":1,"first_seen":"2025-12-03T23:59:59+00:00","last_seen":"2025-12-03T23:59:59+00:00","evidence_fact_ids":[26106]},{"display_name":"Nantahala Capital Management, LLC","detail":"change_of_control","count":1,"first_seen":"2025-04-16T23:59:59+00:00","last_seen":"2025-04-16T23:59:59+00:00","evidence_fact_ids":[85364]},{"display_name":"Surgalign Holdings, Inc.","detail":"acquisition","count":1,"first_seen":"2023-08-10T23:59:59+00:00","last_seen":"2023-08-10T23:59:59+00:00","evidence_fact_ids":[120466]},{"display_name":"Surgalign SPV, Inc.","detail":"acquisition","count":1,"first_seen":"2023-03-01T23:59:59+00:00","last_seen":"2023-03-01T23:59:59+00:00","evidence_fact_ids":[174847]}]},"facts":[{"fact_type":"earnings_release","fact_key":"5ffbe1253535dbc9f8d6cdb80453219d56a57747","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2026-05-13T11:05:34+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"net loss was $3.1 million","period_text":"first quarter ended March 31, 2026","report_date":"2026-05-13","result_type":"reported_results","revenue_text":"$20.9 million"},"claim":"Xtant Medical Holdings, Inc. reported first quarter ended March 31, 2026 results: revenue $20.9 million, net income net loss was $3.1 million. Guidance raised.","evidence_excerpt":"conditions, today reported financial and operating results for the first quarter ended March\n31, 2026. First\nQuarter 2026 Financial Highlights ● Generated\n total revenue of $20.9 million for the first quarter of 2026, as compared to $32.9 million\n for the first quarter of 2025. The decline in revenue relates primarily to the sale of assets\n and businesses to","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-022600","anchor_url":"https://secwatch.observer/filing/0001493152-26-022600#claim-5ffbe1253535dbc9f8d6cdb80453219d56a57747","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315226022600/0001493152-26-022600-index.htm"},{"fact_type":"earnings_release","fact_key":"e0fbf94fbcdd878b7e010e508ee388808fcdbc5c","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2026-03-31T23:59:59+00:00","payload":{"eps_text":"$0.03 per diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$5.0 million","period_text":"Full Year 2025","report_date":"2026-03-31","result_type":"reported_results","revenue_text":"$134.0 million"},"claim":"Xtant Medical Holdings, Inc. reported Full Year 2025 results: revenue $134.0 million, net income $5.0 million, EPS $0.03 per diluted share.","evidence_excerpt":"and may be different from non-GAAP finan\n\n--- EX-99.1 (EX-99.1) ---\n\nXtant\nMedical Reports Fourth Quarter and Full-Year 2025 Financial Results Full\nyear 2025 revenue totals $133.9 million, an increase of 14% year-over-year Xtant\ndelivers positive net income, adjusted EBITDA and operating cash flow Total\ncash of $17.3 million as of December 31, 2025 with an","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-013788","anchor_url":"https://secwatch.observer/filing/0001493152-26-013788#claim-e0fbf94fbcdd878b7e010e508ee388808fcdbc5c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315226013788/0001493152-26-013788-index.htm"},{"fact_type":"earnings_release","fact_key":"3822601bcbf0d73a083746c5acec9ef7d576353d","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2026-03-31T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$0.1 million","period_text":"Fourth Quarter 2025","report_date":"2026-03-31","result_type":"reported_results","revenue_text":"$32.4 million"},"claim":"Xtant Medical Holdings, Inc. reported Fourth Quarter 2025 results: revenue $32.4 million, net income $0.1 million.","evidence_excerpt":"Fourth quarter 2025 revenue grew 3% to $32.4 million, compared to $31.5 million for the same period in 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-013788","anchor_url":"https://secwatch.observer/filing/0001493152-26-013788#claim-3822601bcbf0d73a083746c5acec9ef7d576353d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315226013788/0001493152-26-013788-index.htm"},{"fact_type":"debt_financing","fact_key":"dd18f471463a610e4f67ee0a43179a58968f5f2c","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2025-12-03T23:59:59+00:00","payload":{"counterparty":"MidCap Financial Trust","effective_date":"2025-12-01","event":"acceleration","instrument_type":"term_loan","interest_rate_text":null,"item_codes_triggered":["2.04"],"maturity_text":null,"principal_text":"approximately $8.0 million"},"claim":"Xtant Medical Holdings, Inc. faced acceleration on term loan of approximately $8.0 million with MidCap Financial Trust.","evidence_excerpt":"approximately $8.0 million of the net cash proceeds received by the Company from the Divestitures (including previous deposits received) was used to prepay a portion of the Company’s term loan with MidCap, resulting in $14.4 million remaining outstanding under the term loan as of December 1, 2025, of which up to an additional $1.6 million will be required to be prepaid if and when the Companion Spine Note is repaid by Companion Spine.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-025963","anchor_url":"https://secwatch.observer/filing/0001493152-25-025963#claim-dd18f471463a610e4f67ee0a43179a58968f5f2c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315225025963/0001493152-25-025963-index.htm"},{"fact_type":"ma_transaction","fact_key":"0c7d7a2d1fdbbab6505c3059f07228629e08e8c6","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2025-12-03T23:59:59+00:00","payload":{"action":"disposition","closing_date":"2025-12-01","consideration_text":"$1.7 million","counterparty":"Companion Spine SAS","effective_date":"2025-12-01","item_codes_triggered":["2.01"]},"claim":"Xtant Medical Holdings, Inc. completed a disposition involving Companion Spine SAS for $1.7 million (closed 2025-12-01).","evidence_excerpt":"Companion Spine (the “Paradigm Agreement”\nand together with the Coflex/CoFix Agreement, the “Divestiture Agreements”). The total purchase price of the Paradigm Divestiture\nwas $1.7 million (the “Paradigm Purchase Price”), which was paid to the Company in cash at the closing of the Paradigm Divestiture.\nThe Paradigm Purchase Price is subject to future adjustments","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-025963","anchor_url":"https://secwatch.observer/filing/0001493152-25-025963#claim-0c7d7a2d1fdbbab6505c3059f07228629e08e8c6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315225025963/0001493152-25-025963-index.htm"},{"fact_type":"ma_transaction","fact_key":"e2765e1c7eeb33f34629f925e294e5b8bd485814","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2025-12-03T23:59:59+00:00","payload":{"action":"disposition","closing_date":"2025-12-01","consideration_text":"$17.5 million","counterparty":"Companion Spine, LLC and one of its affiliates, Companion Spine SAS","effective_date":"2025-12-01","item_codes_triggered":["2.01"]},"claim":"Xtant Medical Holdings, Inc. completed a disposition involving Companion Spine, LLC and one of its affiliates, Companion Spine SAS for $17.5 million (closed 2025-12-01).","evidence_excerpt":"Asset Purchase Agreement dated July 7, 2025 between the Seller\nand Companion Spine (the “Coflex/CoFix Agreement”). The total purchase price of the Coflex/CoFix Divestiture was $17.5 million\n(subject to a closing inventory valuation adjustment set forth in the Coflex/CoFix Agreement) (the “Coflex/CoFix Purchase Price”).\nOf the total purchase price, an aggregate of","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-025963","anchor_url":"https://secwatch.observer/filing/0001493152-25-025963#claim-e2765e1c7eeb33f34629f925e294e5b8bd485814","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315225025963/0001493152-25-025963-index.htm"},{"fact_type":"ma_transaction","fact_key":"4978791f40f3707d38a48bfd6c3f84747de9e5e1","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2025-04-16T23:59:59+00:00","payload":{"action":"change_of_control","closing_date":"2025-04-15","consideration_text":"approximately $30.7 million","counterparty":"Nantahala Capital Management, LLC","effective_date":"2025-04-15","item_codes_triggered":["5.01"]},"claim":"Xtant Medical Holdings, Inc. underwent a change of control involving Nantahala Capital Management, LLC for approximately $30.7 million (closed 2025-04-15).","evidence_excerpt":"Pursuant to the Transaction, as described in the Introductory Note hereto, which is incorporated by reference into this Item 5.01, the Purchasers completed the acquisition of the Shares from the Sellers, constituting 52.5% of the Common Stock outstanding as of April 15, 2025 for approximately $30.7 million, which the Company believes was funded out of the Purchasers’ personal funds. The consummation of the Transaction resulted in a change in control of the Company, as a result of which the Sellers own no shares of Common Stock and Nantahala gained effective control of the Company by virtue of holding approximately 49.1% of the Company’s issued and outstanding Common Stock and being the largest stockholder of the Company.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001641172-25-005078","anchor_url":"https://secwatch.observer/filing/0001641172-25-005078#claim-4978791f40f3707d38a48bfd6c3f84747de9e5e1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000164117225005078/0001641172-25-005078-index.htm"},{"fact_type":"earnings_release","fact_key":"cd3702fd247802c2df5971927ea15c469ebe8c8e","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2024-05-15T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"full year 2024","report_date":"2024-05-15","result_type":"guidance_update","revenue_text":"$116 million to $120 million"},"claim":"Xtant Medical Holdings, Inc. reported full year 2024 results: revenue $116 million to $120 million. Guidance raised.","evidence_excerpt":"Xtant Medical raises its expectation for full year 2024 revenue to $116 million to $120 million, up from the Company’s prior guidance of $112 million to $116 million.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-019864","anchor_url":"https://secwatch.observer/filing/0001493152-24-019864#claim-cd3702fd247802c2df5971927ea15c469ebe8c8e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315224019864/0001493152-24-019864-index.htm"},{"fact_type":"earnings_release","fact_key":"53af983d1546628058fcf920368bcd4e11e2822c","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2024-05-15T23:59:59+00:00","payload":{"eps_text":"$0.03 per share","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"$4.3 million, or $0.03 per share","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-15","result_type":"reported_results","revenue_text":"$27.9 million"},"claim":"Xtant Medical Holdings, Inc. reported first quarter ended March 31, 2024 results: revenue $27.9 million, net income $4.3 million, or $0.03 per share, EPS $0.03 per share. Guidance raised.","evidence_excerpt":"treatment of spinal disorders, today reported financial and operating results for the first quarter\nended March 31, 2024. First\nQuarter 2024 Financial Highlights ● Revenue\n of $27.9 million, up 55%, compared to the prior year quarter ● Gross\n margin of 62.1%, up 340 basis points, compared to the prior year quarter ● Net\n loss of $4.4 million compared to $2.1 million","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-019864","anchor_url":"https://secwatch.observer/filing/0001493152-24-019864#claim-53af983d1546628058fcf920368bcd4e11e2822c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315224019864/0001493152-24-019864-index.htm"},{"fact_type":"debt_financing","fact_key":"fe457ca800fc683fae5e8e22f127a3cffad52c53","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2024-03-07T23:59:59+00:00","payload":{"counterparty":"MidCap Funding IV Trust","effective_date":"2024-03-07","event":"amendment","instrument_type":"revolving_credit","interest_rate_text":"SOFR Interest Rate plus 4.50%","item_codes_triggered":["2.03"],"maturity_text":"March 1, 2029","principal_text":"up to $17,000,000"},"claim":"Xtant Medical Holdings, Inc. amended revolving credit of up to $17,000,000 with MidCap Funding IV Trust at SOFR Interest Rate plus 4.50% maturing March 1, 2029.","evidence_excerpt":"and lenders from time to time party thereto. The\nTerm Credit Agreement provides for a secured term loan facility (the “Term Facility”) in an aggregate principal amount of\n$17,000,000, which was previously funded under the Prior Term Credit Agreement, and an additional $10,000,000 tranche available solely\nat the discretion of MidCap Financial Trust and the","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-009247","anchor_url":"https://secwatch.observer/filing/0001493152-24-009247#claim-fe457ca800fc683fae5e8e22f127a3cffad52c53","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315224009247/0001493152-24-009247-index.htm"},{"fact_type":"debt_financing","fact_key":"7b9b884487a773c4353af0eb0e29ce169bc599fe","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2024-03-07T23:59:59+00:00","payload":{"counterparty":"MidCap Financial Trust","effective_date":"2024-03-07","event":"amendment","instrument_type":"credit_facility","interest_rate_text":"SOFR Interest Rate plus 6.50%","item_codes_triggered":["2.03"],"maturity_text":"March 1, 2029","principal_text":"$17,000,000"},"claim":"Xtant Medical Holdings, Inc. amended credit facility of $17,000,000 with MidCap Financial Trust at SOFR Interest Rate plus 6.50% maturing March 1, 2029.","evidence_excerpt":"and lenders from time to time party thereto. The\nTerm Credit Agreement provides for a secured term loan facility (the “Term Facility”) in an aggregate principal amount of\n$17,000,000, which was previously funded under the Prior Term Credit Agreement, and an additional $10,000,000 tranche available solely\nat the discretion of MidCap Financial Trust and the","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-009247","anchor_url":"https://secwatch.observer/filing/0001493152-24-009247#claim-7b9b884487a773c4353af0eb0e29ce169bc599fe","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315224009247/0001493152-24-009247-index.htm"},{"fact_type":"material_agreement","fact_key":"3959cde7f26cc4a8c5520a34370043e43e7c6f4c","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2024-03-07T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Credit Agreements","agreement_type":"credit_facility","counterparty":"MidCap Financial Trust and MidCap Funding IV Trust","effective_date":"2024-03-07","item_codes_triggered":["1.01"],"value_text":"$17,000,000 term facility and $17,000,000 revolving facility"},"claim":"Xtant Medical Holdings, Inc. amended Credit Agreements with MidCap Financial Trust and MidCap Funding IV Trust valued at $17,000,000 term facility and $17,000,000 revolving facility (effective 2024-03-07).","evidence_excerpt":"On March 7, 2024 (the “Closing Date”), Xtant Medical Holdings, Inc. (the “Company”), as guarantor, and certain of its subsidiaries, Xtant Medical, Inc., Bacterin International, Inc., X-spine Systems, Inc. and Surgalign SPV, Inc., as borrowers (collectively, the “Borrowers”), entered into (i) an Amended and Restated Credit, Security and Guaranty Agreement (Term Loan) (the “Term Credit Agreement”) with MidCap Financial Trust, in its capacity as agent, and the lenders from time to time party thereto, and (ii) an Amended and Restated Credit, Security and Guaranty Agreement (Revolving Loan) (the “Revolving Credit Agreement” and, together with the Term Credit Agreement, the “Credit Agreements”) with MidCap Funding IV Trust, in its capacity as agent, and the lenders from time to time party thereto.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-009247","anchor_url":"https://secwatch.observer/filing/0001493152-24-009247#claim-3959cde7f26cc4a8c5520a34370043e43e7c6f4c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315224009247/0001493152-24-009247-index.htm"},{"fact_type":"earnings_release","fact_key":"b03bacb7aed52c137233dc0b5f2adf71a192bb80","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-11-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"full year 2023","report_date":"2023-11-09","result_type":"guidance_update","revenue_text":null},"claim":"Xtant Medical Holdings, Inc. updated its full year 2023 guidance (raised).","evidence_excerpt":"Xtant Medical raises its expectation for full year 2023 revenue to $88 million to $91 million, up from the Company’s prior guidance of $75 million to $77 million.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-039986","anchor_url":"https://secwatch.observer/filing/0001493152-23-039986#claim-b03bacb7aed52c137233dc0b5f2adf71a192bb80","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223039986/0001493152-23-039986-index.htm"},{"fact_type":"earnings_release","fact_key":"7716a9c8cc4ff275d3909450a5f82ae26ab91d02","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-11-09T23:59:59+00:00","payload":{"eps_text":"$0.07 per share","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"$9.2 million, or $0.07 per share","period_text":"third quarter ended September 30, 2023","report_date":"2023-11-09","result_type":"reported_results","revenue_text":"$25.0 million"},"claim":"Xtant Medical Holdings, Inc. reported third quarter ended September 30, 2023 results: revenue $25.0 million, net income $9.2 million, or $0.07 per share, EPS $0.07 per share. Guidance raised.","evidence_excerpt":"Xtant Medical Announces Record Third Quarter Revenue of $25 Million Raises 2023 Annual Revenue Guidance to $88 Million - $91 Million","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-039986","anchor_url":"https://secwatch.observer/filing/0001493152-23-039986#claim-7716a9c8cc4ff275d3909450a5f82ae26ab91d02","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223039986/0001493152-23-039986-index.htm"},{"fact_type":"auditor_change","fact_key":"6ffa04c213760b69fb0baea0d86d355e29494d4d","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-08-18T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"Plante & Moran, PLLC","disagreement_text":null,"effective_date":"2023-08-15","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":"Grant Thornton LLP"},"claim":"Xtant Medical Holdings, Inc. dismissed Plante & Moran, PLLC as its auditor.","evidence_excerpt":"dismissed Plante & Moran, PLLC (“Plante Moran”), as the Company’s independent registered public accounting firm, subject to Grant Thornton LLP’s standard client acceptance procedures, which were completed on August 18, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-029442","anchor_url":"https://secwatch.observer/filing/0001493152-23-029442#claim-6ffa04c213760b69fb0baea0d86d355e29494d4d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223029442/0001493152-23-029442-index.htm"},{"fact_type":"auditor_change","fact_key":"66a70cd2eb5f4efd92fccc4700be334a93083082","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-08-18T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Grant Thornton LLP","disagreement_text":null,"effective_date":"2023-08-15","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"Xtant Medical Holdings, Inc. engaged Grant Thornton LLP as its auditor.","evidence_excerpt":"On August 15, 2023, the Audit Committee of the Board of Directors of Xtant Medical Holdings, Inc. (the “Company”) appointed Grant Thornton LLP (“Grant Thornton”) as the Company’s independent registered public accounting firm","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-029442","anchor_url":"https://secwatch.observer/filing/0001493152-23-029442#claim-66a70cd2eb5f4efd92fccc4700be334a93083082","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223029442/0001493152-23-029442-index.htm"},{"fact_type":"ma_transaction","fact_key":"b2400169b19dbc80bc9678a414c9d600d4de7d97","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-08-10T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2023-08-10","consideration_text":"$5 million","counterparty":"Surgalign Holdings, Inc.","effective_date":"2023-08-10","item_codes_triggered":["2.01"]},"claim":"Xtant Medical Holdings, Inc. completed an acquisition involving Surgalign Holdings, Inc. for $5 million (closed 2023-08-10).","evidence_excerpt":"Seller’s bankruptcy proceedings. The Bankruptcy Court issued\na Sale Order on August 9, 2023 approving and authorizing the Transaction. The Company funded the purchase price of $5 million, plus Liabilities,\nwith cash on hand. The\nforegoing summary of the Asset Purchase Agreement is not complete and is qualified in its entirety by reference to the full text of","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001493152-23-027585","anchor_url":"https://secwatch.observer/filing/0001493152-23-027585#claim-b2400169b19dbc80bc9678a414c9d600d4de7d97","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223027585/0001493152-23-027585-index.htm"},{"fact_type":"material_agreement","fact_key":"ee221183c678aafda63d853e7e3f27152bc628a7","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-08-10T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Limited Consent and Amendment No. 4 to Credit, Security and Guarantee Agreement (Term Loan)","agreement_type":"credit_facility","counterparty":"MidCap Financial Trust","effective_date":"2023-08-10","item_codes_triggered":["1.01","1.02"],"value_text":null},"claim":"Xtant Medical Holdings, Inc. amended Limited Consent and Amendment No. 4 to Credit, Security and Guarantee Agreement (Term Loan) with MidCap Financial Trust (effective 2023-08-10).","evidence_excerpt":"On August 10, 2023, Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), entered into a Limited Consent and Amendment No. 4 to Credit, Security and Guarantee Agreement (Term Loan) (“Term Amendment No. 4\"), which amends the Credit, Security and Guarantee Agreement (Term Loan) by and among the Company, as guarantor, and its U.S. subsidiaries, as borrowers, MidCap Financial Trust, as agent, and the financial institutions party thereto (as amended, the “Term Credit Agreement”), and a Limited Consent and Amendment No. 4 to Credit, Security and Guarantee Agreement (Revolving Loan) (“Revolving Amendment No. 4\"","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-027585","anchor_url":"https://secwatch.observer/filing/0001493152-23-027585#claim-ee221183c678aafda63d853e7e3f27152bc628a7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223027585/0001493152-23-027585-index.htm"},{"fact_type":"earnings_release","fact_key":"6fd2a746eb6ef6de0ce650b04d53de093f82ebd0","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-08-01T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"full year 2023","report_date":"2023-08-01","result_type":"guidance_update","revenue_text":"$75 million to $77 million"},"claim":"Xtant Medical Holdings, Inc. reported full year 2023 results: revenue $75 million to $77 million. Guidance raised.","evidence_excerpt":"Xtant Medical raises its expectation for full year 2023 revenue to $75 million to $77 million, up from the Company's prior guidance of $73 million to $75 million.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-026160","anchor_url":"https://secwatch.observer/filing/0001493152-23-026160#claim-6fd2a746eb6ef6de0ce650b04d53de093f82ebd0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223026160/0001493152-23-026160-index.htm"},{"fact_type":"earnings_release","fact_key":"52fc0523bfa4701925e7e0832635f16f142ebc87","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-08-01T23:59:59+00:00","payload":{"eps_text":"-$0.02","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"-$2.2 million","period_text":"second quarter ended June 30, 2023","report_date":"2023-08-01","result_type":"reported_results","revenue_text":null},"claim":"Xtant Medical Holdings, Inc. reported second quarter ended June 30, 2023 results: net income -$2.2 million, EPS -$0.02.","evidence_excerpt":"Second quarter 2023 revenue grew 32%, representing organic growth of 14% plus an 18% increase from products added in the acquisition of the Coflex and CoFix lines, to $20.2 million, compared to $15.3 million for the same period in 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-026160","anchor_url":"https://secwatch.observer/filing/0001493152-23-026160#claim-52fc0523bfa4701925e7e0832635f16f142ebc87","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223026160/0001493152-23-026160-index.htm"},{"fact_type":"governance_change","fact_key":"90d75bd2130ad0bb6221108c3efad7d07816545a","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-07-28T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-07-26","item_codes_triggered":["5.03"],"summary_text":"Stockholders approved three charter amendments: (1) requiring supermajority director vote to fix number of directors above seven; (2) eliminating/limiting officer personal liability per Delaware law; (3) amending exclusive forum provision."},"claim":"Xtant Medical Holdings, Inc.: Stockholders approved three charter amendments: (1) requiring supermajority director vote to fix number of directors above seven; (2) eliminating/limiting officer personal liability per Delaware law; (3) amending exclusive forum provision (effective 2023-07-26).","evidence_excerpt":"At the Company’s 2023 annual meeting of stockholders held on July 26, 2023, the Company’s stockholders approved the following three amendments to the Company’s Amended and Restated Certificate of Incorporation, as amended (collectively, the “Charter Amendments”): ● an amendment requiring a supermajority director vote to fix the number of directors of the Company at more than seven; ● an amendment to eliminate or limit the personal liability of the Company’s officers to the extent permitted by recent amendments to the Delaware General Corporation Law; and ● an amendment to amend the Company’s exclusive forum provision.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-025769","anchor_url":"https://secwatch.observer/filing/0001493152-23-025769#claim-90d75bd2130ad0bb6221108c3efad7d07816545a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223025769/0001493152-23-025769-index.htm"},{"fact_type":"shareholder_vote","fact_key":"69fc41284442ebcdf7877baedee0a7c4228363a0","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-07-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-07-26","outcome":"passed","proposal_text":"Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":"8,179,094","subject":null,"votes_abstain":"4,529","votes_against":"145,378","votes_for":"87,213,652","votes_withheld":null}]},"claim":"Xtant Medical Holdings, Inc. shareholders approved Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan at the 2023-07-26 meeting.","evidence_excerpt":"Proposal Seven - The Company's stockholders approved the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan by the following final voting results:","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-025769","anchor_url":"https://secwatch.observer/filing/0001493152-23-025769#claim-69fc41284442ebcdf7877baedee0a7c4228363a0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223025769/0001493152-23-025769-index.htm"},{"fact_type":"shareholder_vote","fact_key":"e1d5174be3c83528258ec0e86ee89e8ced85387e","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-07-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-07-26","outcome":"passed","proposal_text":"Charter Amendment amending exclusive forum provision","proposal_type":"charter_amendment","results":[{"broker_non_votes":"8,179,094","subject":null,"votes_abstain":"8,560","votes_against":"351,698","votes_for":"87,003,301","votes_withheld":null}]},"claim":"Xtant Medical Holdings, Inc. shareholders approved Charter Amendment amending exclusive forum provision at the 2023-07-26 meeting.","evidence_excerpt":"Proposal Six - The Company's stockholders approved the Charter Amendment amending the Company's exclusive forum provision by the following final voting results:","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-025769","anchor_url":"https://secwatch.observer/filing/0001493152-23-025769#claim-e1d5174be3c83528258ec0e86ee89e8ced85387e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223025769/0001493152-23-025769-index.htm"},{"fact_type":"shareholder_vote","fact_key":"a46653ab1874b3d10c3087098b9ce435c9e454fb","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-07-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-07-26","outcome":"passed","proposal_text":"Charter Amendment requiring supermajority director vote to fix number of directors at more than seven","proposal_type":"charter_amendment","results":[{"broker_non_votes":"8,179,094","subject":null,"votes_abstain":"4,683","votes_against":"643,269","votes_for":"86,715,607","votes_withheld":null}]},"claim":"Xtant Medical Holdings, Inc. shareholders approved Charter Amendment requiring supermajority director vote to fix number of directors at more than seven at the 2023-07-26 meeting.","evidence_excerpt":"Proposal Five - The Company's stockholders approved the Charter Amendment requiring a supermajority director vote to fix the number of directors of the Company at more than seven by the following final voting results:","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-025769","anchor_url":"https://secwatch.observer/filing/0001493152-23-025769#claim-a46653ab1874b3d10c3087098b9ce435c9e454fb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223025769/0001493152-23-025769-index.htm"},{"fact_type":"shareholder_vote","fact_key":"add1e5d1fd00d264e5a58db078e9928344a021a9","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-07-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-07-26","outcome":"passed","proposal_text":"Charter Amendment eliminating or limiting personal liability of officers","proposal_type":"charter_amendment","results":[{"broker_non_votes":"8,179,094","subject":null,"votes_abstain":"4,528","votes_against":"422,510","votes_for":"86,936,521","votes_withheld":null}]},"claim":"Xtant Medical Holdings, Inc. shareholders approved Charter Amendment eliminating or limiting personal liability of officers at the 2023-07-26 meeting.","evidence_excerpt":"Proposal Four - The Company's stockholders approved the Charter Amendment eliminating or limiting the personal liability of the Company's officers to the extent permitted by recent amendments to the Delaware General Corporation Law by the following final voting results:","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-025769","anchor_url":"https://secwatch.observer/filing/0001493152-23-025769#claim-add1e5d1fd00d264e5a58db078e9928344a021a9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223025769/0001493152-23-025769-index.htm"},{"fact_type":"shareholder_vote","fact_key":"05ce001d34d895138b350a73afbe89b0d99dbeab","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-07-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-07-26","outcome":"passed","proposal_text":"Advisory approval of executive compensation","proposal_type":"say_on_pay","results":[{"broker_non_votes":"8,179,094","subject":null,"votes_abstain":"9,379","votes_against":"127,672","votes_for":"87,226,508","votes_withheld":null}]},"claim":"Xtant Medical Holdings, Inc. shareholders approved Advisory approval of executive compensation at the 2023-07-26 meeting.","evidence_excerpt":"Proposal Three - The Company's stockholders approved, on an advisory basis, the compensation of the Company's executive officers named in the 2023 Proxy Statement by the following final voting results:","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-025769","anchor_url":"https://secwatch.observer/filing/0001493152-23-025769#claim-05ce001d34d895138b350a73afbe89b0d99dbeab","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223025769/0001493152-23-025769-index.htm"},{"fact_type":"shareholder_vote","fact_key":"10ef3d01ce1b69927f0e0b2f771ff819db0f07c3","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-07-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-07-26","outcome":"passed","proposal_text":"Ratification of appointment of Plante & Moran, PLLC as independent registered public accounting firm for 2023","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"2,892","votes_against":"11,624","votes_for":"95,528,137","votes_withheld":null}]},"claim":"Xtant Medical Holdings, Inc. shareholders approved Ratification of appointment of Plante & Moran, PLLC as independent registered public accounting firm for 2023 at the 2023-07-26 meeting.","evidence_excerpt":"Proposal Two - The Company's stockholders ratified the appointment of Plante & Moran, PLLC as the Company's independent registered public accounting firm for the year ending December 31, 2023 by the following final voting results:","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-025769","anchor_url":"https://secwatch.observer/filing/0001493152-23-025769#claim-10ef3d01ce1b69927f0e0b2f771ff819db0f07c3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223025769/0001493152-23-025769-index.htm"},{"fact_type":"shareholder_vote","fact_key":"75e170caacd748b82168432e73fda7aad6c460da","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-07-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-07-26","outcome":"passed","proposal_text":"Election of six director nominees","proposal_type":"director_election","results":[{"broker_non_votes":"8,179,094","subject":"John Bakewell","votes_abstain":null,"votes_against":null,"votes_for":"86,937,647","votes_withheld":"425,912"},{"broker_non_votes":"8,179,094","subject":"Jonn Beeson","votes_abstain":null,"votes_against":null,"votes_for":"87,345,686","votes_withheld":"17,873"},{"broker_non_votes":"8,179,094","subject":"Sean E. Browne","votes_abstain":null,"votes_against":null,"votes_for":"87,290,919","votes_withheld":"72,640"},{"broker_non_votes":"8,179,094","subject":"Robert McNamara","votes_abstain":null,"votes_against":null,"votes_for":"87,073,202","votes_withheld":"290,357"},{"broker_non_votes":"8,179,094","subject":"Lori Mitchell-Keller","votes_abstain":null,"votes_against":null,"votes_for":"87,347,120","votes_withheld":"16,439"},{"broker_non_votes":"8,179,094","subject":"Stavros Vizirgianakis","votes_abstain":null,"votes_against":null,"votes_for":"87,312,024","votes_withheld":"51,535"}]},"claim":"Xtant Medical Holdings, Inc. shareholders approved Election of six director nominees at the 2023-07-26 meeting.","evidence_excerpt":"Proposal One - The six director nominees proposed by the Board were elected to serve as members of the Board until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified by the following final voting results:","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-025769","anchor_url":"https://secwatch.observer/filing/0001493152-23-025769#claim-75e170caacd748b82168432e73fda7aad6c460da","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223025769/0001493152-23-025769-index.htm"},{"fact_type":"material_agreement","fact_key":"9df7a3f2d9563540092827358b7c86f51b10356c","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-07-11T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Asset Purchase Agreement","agreement_type":"asset_purchase","counterparty":"Surgalign Holdings, Inc.","effective_date":"2023-07-10","item_codes_triggered":["1.01"],"value_text":"$5 million in cash"},"claim":"Xtant Medical Holdings, Inc. amended Asset Purchase Agreement with Surgalign Holdings, Inc. valued at $5 million in cash (effective 2023-07-10).","evidence_excerpt":"On July 10, 2023, the Company and the Seller entered into a First Amendment to Asset Purchase Agreement (the “Amendment”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-024228","anchor_url":"https://secwatch.observer/filing/0001493152-23-024228#claim-9df7a3f2d9563540092827358b7c86f51b10356c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223024228/0001493152-23-024228-index.htm"},{"fact_type":"earnings_release","fact_key":"c9f143017fd98a46bfeaa8775cfb20474519b82b","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-07-03T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended June 30, 2023","report_date":"2023-07-03","result_type":"guidance_update","revenue_text":null},"claim":"Xtant Medical Holdings, Inc. updated its the quarter ended June 30, 2023 guidance (initiated).","evidence_excerpt":"On July 3, 2023, the Company made available an investor presentation (the “Investor Presentation”), which contains certain financial guidance, including for the quarter ended June 30, 2023","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001493152-23-023229","anchor_url":"https://secwatch.observer/filing/0001493152-23-023229#claim-c9f143017fd98a46bfeaa8775cfb20474519b82b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223023229/0001493152-23-023229-index.htm"},{"fact_type":"material_agreement","fact_key":"0e572ae5abfadc64cf7cac8dd2ce80a79d8dab62","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-07-03T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Placement Agent Agreement","agreement_type":"underwriting","counterparty":"Craig-Hallum Capital Group LLC","effective_date":null,"item_codes_triggered":["1.01"],"value_text":null},"claim":"Xtant Medical Holdings, Inc. entered into Placement Agent Agreement with Craig-Hallum Capital Group LLC.","evidence_excerpt":"the Company entered into an engagement letter with Craig-Hallum Capital Group LLC (the “Placement Agent”) pursuant to which the Placement Agent is serving as the Company’s placement agent in connection with the Private Placement (the “Placement Agent Agreement”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-023229","anchor_url":"https://secwatch.observer/filing/0001493152-23-023229#claim-0e572ae5abfadc64cf7cac8dd2ce80a79d8dab62","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223023229/0001493152-23-023229-index.htm"},{"fact_type":"material_agreement","fact_key":"aa582f16288b78f92b4aa88172776c12861b926c","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-07-03T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"accredited investors (the \"Investors\")","effective_date":"2023-07-03","item_codes_triggered":["1.01"],"value_text":"$15.0 million"},"claim":"Xtant Medical Holdings, Inc. entered into Securities Purchase Agreement with accredited investors (the \"Investors\") valued at $15.0 million (effective 2023-07-03).","evidence_excerpt":"On July 3, 2023, Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with accredited investors (the “Investors”), pursuant to which the Company agreed to issue an aggregate of 20,000,000 shares (the “Shares”) of common stock, par value $0.000001 per share (the “Common Stock”), in a private placement (the “Private Placement”), at a per Share purchase price of $0.75.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-023229","anchor_url":"https://secwatch.observer/filing/0001493152-23-023229#claim-aa582f16288b78f92b4aa88172776c12861b926c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223023229/0001493152-23-023229-index.htm"},{"fact_type":"material_agreement","fact_key":"7a5d66badf5625f3e4bab85f06d9e2379a5ab113","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-06-20T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Asset Purchase Agreement","agreement_type":"asset_purchase","counterparty":"Surgalign Holdings, Inc.","effective_date":"2023-06-18","item_codes_triggered":["1.01"],"value_text":"$5 million"},"claim":"Xtant Medical Holdings, Inc. entered into Asset Purchase Agreement with Surgalign Holdings, Inc. valued at $5 million (effective 2023-06-18).","evidence_excerpt":"On June 18, 2023, Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Surgalign Holdings, Inc., a Delaware corporation (the “Seller”), pursuant to which, subject to the terms and conditions set forth in the Asset Purchase Agreement, the Company agreed to acquire certain assets of the Seller and its subsidiaries on an as-is, where-is basis, including specified inventory, intellectual property and intellectual property rights, contracts, equipment and other personal property, records, all outstanding equity securities of the Seller’s international subsidiaries, and intangibles related to the business of designing, developing and manufacturing hardware medical technology and distributing biologics medical technology, as conducted by the Seller and its subsidiaries (collectively, the “Assets”), and assume certain specified liabilities of the Seller and its subsidiaries (collectively, the “Liabi","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-021783","anchor_url":"https://secwatch.observer/filing/0001493152-23-021783#claim-7a5d66badf5625f3e4bab85f06d9e2379a5ab113","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223021783/0001493152-23-021783-index.htm"},{"fact_type":"governance_change","fact_key":"926d5d0e1c057f77b79c259de06ee08c2855048e","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-05-19T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2023-06-01","item_codes_triggered":["5.03"],"summary_text":"Adopted Third Amended and Restated Bylaws incorporating amendments including universal proxy rules and DGCL updates."},"claim":"Xtant Medical Holdings, Inc.: Adopted Third Amended and Restated Bylaws incorporating amendments including universal proxy rules and DGCL updates (effective 2023-06-01).","evidence_excerpt":"On May 16, 2023, the Board of Directors (the “Board”) of Xtant Medical Holdings, Inc. (the “Company”) approved and adopted Third Amended and Restated Bylaws (the “Amended and Restated Bylaws”) incorporating certain amendments, including amendments in response to the new universal proxy rules promulgated by the Securities and Exchange Commission (the “SEC”) and recent amendments to the Delaware General Corporation Law (the “DGCL”). The Amended and Restated Bylaws will become effective June 1, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-018330","anchor_url":"https://secwatch.observer/filing/0001493152-23-018330#claim-926d5d0e1c057f77b79c259de06ee08c2855048e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223018330/0001493152-23-018330-index.htm"},{"fact_type":"executive_change","fact_key":"c1731a6fa6","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-05-18T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-05-16","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Lori D. Mitchell-Keller was elected as Director at Xtant Medical Holdings, Inc..","evidence_excerpt":"On May 16, 2023, the Board of Directors (the “Board”) of Xtant Medical Holdings, Inc. (the “Company”) elected Lori D. Mitchell-Keller to the Board, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-018040","anchor_url":"https://secwatch.observer/filing/0001493152-23-018040#claim-c1731a6fa6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223018040/0001493152-23-018040-index.htm"},{"fact_type":"earnings_release","fact_key":"66cd38096a3073785f08639229513e1361f2cf96","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-05-04T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"full year 2023","report_date":"2023-05-04","result_type":"guidance_update","revenue_text":"$73 million to $75 million"},"claim":"Xtant Medical Holdings, Inc. reported full year 2023 results: revenue $73 million to $75 million. Guidance initiated.","evidence_excerpt":"Xtant Medical expects full year 2023 revenue of $73 million to $75 million, representing annual growth of approximately 26% to 29% compared to full year 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-015373","anchor_url":"https://secwatch.observer/filing/0001493152-23-015373#claim-66cd38096a3073785f08639229513e1361f2cf96","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223015373/0001493152-23-015373-index.htm"},{"fact_type":"earnings_release","fact_key":"e721fce55c8e28e0e496294de6dbe87f56834d3e","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-05-04T23:59:59+00:00","payload":{"eps_text":"$0.02 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$2.1 million, or $0.02 per share","period_text":"first quarter ended March 31, 2023","report_date":"2023-05-04","result_type":"reported_results","revenue_text":"$17.9 million"},"claim":"Xtant Medical Holdings, Inc. reported first quarter ended March 31, 2023 results: revenue $17.9 million, net income $2.1 million, or $0.02 per share, EPS $0.02 per share.","evidence_excerpt":"2023 Financial Results First\nquarter 2023 revenue grew 38%, including organic growth of 29% and a 9% contribution from the acquisition of the Coflex and CoFix product\nlines, to $17.9 million, compared to $13.0 million for the same period in 2022. The increase in revenue was attributed primarily to greater\nindependent agent sales and sales from the recently acquired","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-015373","anchor_url":"https://secwatch.observer/filing/0001493152-23-015373#claim-e721fce55c8e28e0e496294de6dbe87f56834d3e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223015373/0001493152-23-015373-index.htm"},{"fact_type":"executive_change","fact_key":"a8ba655bc3","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-05-04T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-05-01","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Matthew Rizzo resigned as Director at Xtant Medical Holdings, Inc..","evidence_excerpt":"Michael Eggenberg and Matthew Rizzo resigned as directors of the Company, effective immediately upon the date in which the Board elected Jonn R. Beeson as a director.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-015371","anchor_url":"https://secwatch.observer/filing/0001493152-23-015371#claim-a8ba655bc3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223015371/0001493152-23-015371-index.htm"},{"fact_type":"executive_change","fact_key":"4e53407e5c","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-05-04T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-05-01","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Michael Eggenberg resigned as Director at Xtant Medical Holdings, Inc..","evidence_excerpt":"Michael Eggenberg and Matthew Rizzo resigned as directors of the Company, effective immediately upon the date in which the Board elected Jonn R. Beeson as a director.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-015371","anchor_url":"https://secwatch.observer/filing/0001493152-23-015371#claim-4e53407e5c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223015371/0001493152-23-015371-index.htm"},{"fact_type":"executive_change","fact_key":"baa0f3df79","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-05-04T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-05-01","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Jonn R. Beeson was elected as Director at Xtant Medical Holdings, Inc..","evidence_excerpt":"On May 1, 2023, the Board of Directors (the “Board”) of Xtant Medical Holdings, Inc. (the “Company”) elected Jonn R. Beeson to the Board, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-015371","anchor_url":"https://secwatch.observer/filing/0001493152-23-015371#claim-baa0f3df79","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223015371/0001493152-23-015371-index.htm"},{"fact_type":"earnings_release","fact_key":"4de82a18256326d75c122e7f73065d5e9cb00a1b","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-03-07T23:59:59+00:00","payload":{"eps_text":"$0.02 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$0.02 per share","period_text":"the fourth quarter and year ended December 31, 2022","report_date":"2023-03-07","result_type":"reported_results","revenue_text":"$15.3 million"},"claim":"Xtant Medical Holdings, Inc. reported the fourth quarter and year ended December 31, 2022 results: revenue $15.3 million, net income $0.02 per share, EPS $0.02 per share.","evidence_excerpt":"network, all of which are core focus areas to our long-term growth strategy.” Fourth\nQuarter and Full Year 2022 Financial Results Fourth\nquarter 2022 revenue grew 9% to $15.3 million, compared to $14.0 million for the same quarter in 2021. Full year 2022 revenue was $58.0\nmillion, compared to $55.3 million for 2021. The increase in revenue was largely","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001493152-23-006880","anchor_url":"https://secwatch.observer/filing/0001493152-23-006880#claim-4de82a18256326d75c122e7f73065d5e9cb00a1b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223006880/0001493152-23-006880-index.htm"},{"fact_type":"ma_transaction","fact_key":"478b94bb80700e3a7c7c5395640758b59549996c","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-03-01T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2023-02-28","consideration_text":"$17.0 million in cash","counterparty":"Surgalign SPV, Inc.","effective_date":"2023-02-28","item_codes_triggered":["2.01"]},"claim":"Xtant Medical Holdings, Inc. completed an acquisition involving Surgalign SPV, Inc. for $17.0 million in cash (closed 2023-02-28).","evidence_excerpt":"Seller agreed to sell to the Company, and the Company agreed to purchase from Seller, all of the issued and outstanding shares of common stock of Surgalign SPV, which shares constitute all of the outstanding equity of Surgalign SPV, for an aggregate purchase price of $17.0 million in cash (the “Purchase Price”). The closing contemplated by the Equity Purchase Agreement occurred on February 28, 2023 (the “Closing”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-006396","anchor_url":"https://secwatch.observer/filing/0001493152-23-006396#claim-478b94bb80700e3a7c7c5395640758b59549996c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223006396/0001493152-23-006396-index.htm"},{"fact_type":"debt_financing","fact_key":"9a5d862a2e8d291ddd17c331498a3b3b7dceccee","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-03-01T23:59:59+00:00","payload":{"counterparty":"MidCap Financial Trust","effective_date":"2023-02-28","event":"amendment","instrument_type":"credit_facility","interest_rate_text":"SOFR rate plus the applicable margin of 7.00%","item_codes_triggered":["2.03"],"maturity_text":"May 1, 2026","principal_text":"additional $5.0 million"},"claim":"Xtant Medical Holdings, Inc. amended credit facility of additional $5.0 million with MidCap Financial Trust at SOFR rate plus the applicable margin of 7.00% maturing May 1, 2026.","evidence_excerpt":"On February 28, 2023, the Company entered into the Term Amendment No. 3, which provided an additional $5.0 million under the Term Credit Agreement","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-006396","anchor_url":"https://secwatch.observer/filing/0001493152-23-006396#claim-9a5d862a2e8d291ddd17c331498a3b3b7dceccee","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223006396/0001493152-23-006396-index.htm"},{"fact_type":"material_agreement","fact_key":"442a9bd43ddc2d1dbe879e27977199bc98663088","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-03-01T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment No. 3 to Credit, Security and Guarantee Agreement (Revolving Loan)","agreement_type":"credit_facility","counterparty":"MidCap Funding IV Trust (as agent) and the financial institutions party thereto","effective_date":"2023-02-28","item_codes_triggered":["1.01"],"value_text":null},"claim":"Xtant Medical Holdings, Inc. amended Amendment No. 3 to Credit, Security and Guarantee Agreement (Revolving Loan) with MidCap Funding IV Trust (as agent) and the financial institutions party thereto (effective 2023-02-28).","evidence_excerpt":"In addition to the Term Amendment No. 3., the Company entered into an Amendment No. 3 to Credit, Security and Guarantee Agreement (Revolving Loan) (“Revolving Amendment No. 3” and, together with the Term Amendment No. 3, the “Amendments No. 3”), which amends the Credit, Security and Guarantee Agreement (Revolving Loan), by and among the Company, as guarantor, and its subsidiaries, as borrowers, and MidCap Funding IV Trust, as agent, and the financial institutions party thereto (the “Revolving Credit Agreement”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-006396","anchor_url":"https://secwatch.observer/filing/0001493152-23-006396#claim-442a9bd43ddc2d1dbe879e27977199bc98663088","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223006396/0001493152-23-006396-index.htm"},{"fact_type":"material_agreement","fact_key":"4683232c2fdc064c5ef26b5e9bc638eee172205a","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-03-01T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment No. 3 to Credit, Security and Guarantee Agreement (Term Loan)","agreement_type":"credit_facility","counterparty":"MidCap Financial Trust (as agent) and the financial institutions party thereto","effective_date":"2023-02-28","item_codes_triggered":["1.01"],"value_text":null},"claim":"Xtant Medical Holdings, Inc. amended Amendment No. 3 to Credit, Security and Guarantee Agreement (Term Loan) with MidCap Financial Trust (as agent) and the financial institutions party thereto (effective 2023-02-28).","evidence_excerpt":"The Company funded the Purchase Price with cash on hand and approximately $5.0 million of indebtedness incurred under its Credit, Security and Guarantee Agreement (Term Loan) by and among the Company, as guarantor, and its subsidiaries, as borrowers, MidCap Financial Trust, as agent, and the financial institutions party thereto (the “Term Credit Agreement”), which was amended on February 28, 2023 pursuant to an Amendment No. 3 to Credit, Security and Guarantee Agreement (Term Loan) (“Term Amendment No. 3”) to provide such funding.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-006396","anchor_url":"https://secwatch.observer/filing/0001493152-23-006396#claim-4683232c2fdc064c5ef26b5e9bc638eee172205a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223006396/0001493152-23-006396-index.htm"},{"fact_type":"material_agreement","fact_key":"41038c3f7f09b8d0ed08aade8ccc86e51cbae016","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-03-01T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Transition Services Agreement","agreement_type":"other","counterparty":"Surgalign SPV, Inc. and Seller","effective_date":"2023-02-28","item_codes_triggered":["1.01"],"value_text":null},"claim":"Xtant Medical Holdings, Inc. entered into Transition Services Agreement with Surgalign SPV, Inc. and Seller (effective 2023-02-28).","evidence_excerpt":"In conjunction with the Equity Purchase Agreement, on February 28, 2023, the Company entered into a Transition Services Agreement (“Transition Services Agreement”) with Surgalign SVP and Seller, whereby Seller agreed to provide, or cause to be provided, to the Company and its affiliates on and after the effective date of the Equity Purchase Agreement, after giving effect to the Closing, certain transitional services related to the transition of the Coflex Business.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-006396","anchor_url":"https://secwatch.observer/filing/0001493152-23-006396#claim-41038c3f7f09b8d0ed08aade8ccc86e51cbae016","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223006396/0001493152-23-006396-index.htm"},{"fact_type":"material_agreement","fact_key":"4a1f7eee57ffc11287dcceaa08c3a1a103b7f8a6","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-03-01T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Equity Purchase Agreement","agreement_type":"asset_purchase","counterparty":"Surgalign SPV, Inc., Surgalign Spine Technologies, Inc. (Seller), and Surgalign Holdings, Inc.","effective_date":"2023-02-28","item_codes_triggered":["1.01"],"value_text":"$17.0 million"},"claim":"Xtant Medical Holdings, Inc. entered into Equity Purchase Agreement with Surgalign SPV, Inc., Surgalign Spine Technologies, Inc. (Seller), and Surgalign Holdings, Inc. valued at $17.0 million (effective 2023-02-28).","evidence_excerpt":"On February 28, 2023, Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), entered into an Equity Purchase Agreement (the “Equity Purchase Agreement”) with Surgalign SPV, Inc. (“Surgalign SPV”), a Delaware corporation and wholly owned subsidiary of Surgalign Spine Technologies, Inc., a Delaware corporation (“Seller”), Seller and Surgalign Holdings, Inc., a Delaware corporation, pursuant to which Seller agreed to sell to the Company, and the Company agreed to purchase from Seller, all of the issued and outstanding shares of common stock of Surgalign SPV, which shares constitute all of the outstanding equity of Surgalign SPV, for an aggregate purchase price of $17.0 million in cash (the “Purchase Price”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-006396","anchor_url":"https://secwatch.observer/filing/0001493152-23-006396#claim-4a1f7eee57ffc11287dcceaa08c3a1a103b7f8a6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223006396/0001493152-23-006396-index.htm"},{"fact_type":"executive_change","fact_key":"faa7558f99","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-01-09T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-01-16","interim":false,"role":"Chief Operations Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Mark A. Schallenberger was appointed as Chief Operations Officer at Xtant Medical Holdings, Inc..","evidence_excerpt":"On January 9, 2023, Xtant Medical Holdings, Inc. (the “Company”) announced the appointment of Mark A. Schallenberger as Chief Operations Officer, effective as of January 16, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-000906","anchor_url":"https://secwatch.observer/filing/0001493152-23-000906#claim-faa7558f99","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223000906/0001493152-23-000906-index.htm"},{"fact_type":"earnings_release","fact_key":"1e7439067f44acb7040a689653c5c53badc7fec2","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2022-11-03T23:59:59+00:00","payload":{"eps_text":"$0.03 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$2.4 million","period_text":"third quarter ended September 30, 2022","report_date":"2022-11-03","result_type":"reported_results","revenue_text":"$14.5 million"},"claim":"Xtant Medical Holdings, Inc. reported third quarter ended September 30, 2022 results: revenue $14.5 million, net income $2.4 million, EPS $0.03 per share.","evidence_excerpt":"by the first quarter of 2023 enabling our team to take advantage of the robust demand environment.” Third\nQuarter 2022 Financial Results Third\nquarter 2022 revenue was $14.5 million, compared to $13.8 million for the same quarter in 2021. The increase in revenue was largely attributable\nto introductions of new products. Gross\nmargin for the third quarter of","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-22-030277","anchor_url":"https://secwatch.observer/filing/0001493152-22-030277#claim-1e7439067f44acb7040a689653c5c53badc7fec2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315222030277/0001493152-22-030277-index.htm"},{"fact_type":"shareholder_vote","fact_key":"7f3577cf0bf2a210b6604e05efd61f26e90371bc","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2022-10-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-10-26","outcome":"passed","proposal_text":"Approval of Second Amended and Restated 2018 Equity Incentive Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":"2,002,504","subject":null,"votes_abstain":"3,618","votes_against":"809,383","votes_for":"82,054,439","votes_withheld":null}]},"claim":"Xtant Medical Holdings, Inc. shareholders approved Approval of Second Amended and Restated 2018 Equity Incentive Plan at the 2022-10-26 meeting.","evidence_excerpt":"Proposal No. 4 - The Xtant Medical Holdings, Inc. Second Amended and Restated 2018 Equity Incentive Plan was approved by the following final voting results: Votes For Votes Against Votes Abstained Broker Non-Votes 82,054,439 809,383 3,618 2,002,504","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-22-029849","anchor_url":"https://secwatch.observer/filing/0001493152-22-029849#claim-7f3577cf0bf2a210b6604e05efd61f26e90371bc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315222029849/0001493152-22-029849-index.htm"},{"fact_type":"shareholder_vote","fact_key":"fedae768ab7ada7b22140cf704e7652e4388885c","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2022-10-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-10-26","outcome":"passed","proposal_text":"Advisory vote on executive compensation","proposal_type":"say_on_pay","results":[{"broker_non_votes":"2,002,504","subject":null,"votes_abstain":"6,693","votes_against":"56,671","votes_for":"82,804,076","votes_withheld":null}]},"claim":"Xtant Medical Holdings, Inc. shareholders approved Advisory vote on executive compensation at the 2022-10-26 meeting.","evidence_excerpt":"Proposal No. 3 - The compensation of the Company’s executive officers named in the proxy statement was approved, on an advisory basis, by the following final voting results: Votes For Votes Against Votes Abstained Broker Non-Votes 82,804,076 56,671 6,693 2,002,504","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-22-029849","anchor_url":"https://secwatch.observer/filing/0001493152-22-029849#claim-fedae768ab7ada7b22140cf704e7652e4388885c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315222029849/0001493152-22-029849-index.htm"},{"fact_type":"shareholder_vote","fact_key":"2a747a17378fe1bfeba80a9f9135ee1bc25414fd","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2022-10-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-10-26","outcome":"passed","proposal_text":"Ratification of appointment of independent registered public accounting firm","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"12,658","votes_against":"12,191","votes_for":"84,845,095","votes_withheld":null}]},"claim":"Xtant Medical Holdings, Inc. shareholders approved Ratification of appointment of independent registered public accounting firm at the 2022-10-26 meeting.","evidence_excerpt":"Proposal No. 2 - The ratification of the appointment of Plante & Moran, PLLC as the Company’s independent registered public accounting firm for the year ending December 31, 2022 was approved by the following final voting results: Votes For Votes Against Votes Abstained Broker Non-Votes 84,845,095 12,191 12,658 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-22-029849","anchor_url":"https://secwatch.observer/filing/0001493152-22-029849#claim-2a747a17378fe1bfeba80a9f9135ee1bc25414fd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315222029849/0001493152-22-029849-index.htm"},{"fact_type":"shareholder_vote","fact_key":"e15add673da33e38f4da9a532d9c9d390e464e6e","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2022-10-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-10-26","outcome":"passed","proposal_text":"Election of six director nominees","proposal_type":"director_election","results":[{"broker_non_votes":"2,002,504","subject":"John Bakewell","votes_abstain":null,"votes_against":null,"votes_for":"82,400,159","votes_withheld":"467,281"},{"broker_non_votes":"2,002,504","subject":"Sean E. Browne","votes_abstain":null,"votes_against":null,"votes_for":"81,806,196","votes_withheld":"1,061,244"},{"broker_non_votes":"2,002,504","subject":"Michael Eggenberg","votes_abstain":null,"votes_against":null,"votes_for":"81,755,204","votes_withheld":"1,112,236"},{"broker_non_votes":"2,002,504","subject":"Robert McNamara","votes_abstain":null,"votes_against":null,"votes_for":"82,387,100","votes_withheld":"480,340"},{"broker_non_votes":"2,002,504","subject":"Matthew Rizzo","votes_abstain":null,"votes_against":null,"votes_for":"81,755,616","votes_withheld":"1,111,824"},{"broker_non_votes":"2,002,504","subject":"Stavros Vizirgianakis","votes_abstain":null,"votes_against":null,"votes_for":"81,782,213","votes_withheld":"1,085,227"}]},"claim":"Xtant Medical Holdings, Inc. shareholders approved Election of six director nominees at the 2022-10-26 meeting.","evidence_excerpt":"Proposal No. 1 - The six director nominees proposed by the Board were elected to serve as members of the Board until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified by the following final voting results: Votes For Votes Withheld Broker Non-Votes John Bakewell 82,400,159 467,281 2,002,504 Sean E. Browne 81,806,196 1,061,244 2,002,504 Michael Eggenberg 81,755,204 1,112,236 2,002,504 Robert McNamara 82,387,100 480,340 2,002,504 Matthew Rizzo 81,755,616 1,111,824 2,002,504 Stavros Vizirgianakis 81,782,213 1,085,227 2,002,504","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-22-029849","anchor_url":"https://secwatch.observer/filing/0001493152-22-029849#claim-e15add673da33e38f4da9a532d9c9d390e464e6e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315222029849/0001493152-22-029849-index.htm"},{"fact_type":"executive_change","fact_key":"bafbb1da17","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2022-08-31T23:59:59+00:00","payload":{"action":"replaced","action_category":"role_change","departure_tone":"routine","effective_date":"2022-08-31","interim":false,"role":"Chairman of the Board","role_category":"chair","successor_name":"Stavros Vizirgianakis","successor_named":true},"claim":"Jeffrey Peters changed role as Chairman of the Board at Xtant Medical Holdings, Inc..","evidence_excerpt":"the Board elected Mr. Vizirgianakis as Chairman of the Board, effective upon completion of the First Closing, to replace Jeffrey Peters, who previously served as Chairman of the Board and intends not to stand for re-election at the Company’s next annual meeting of stockholders","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-22-024444","anchor_url":"https://secwatch.observer/filing/0001493152-22-024444#claim-bafbb1da17","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315222024444/0001493152-22-024444-index.htm"},{"fact_type":"executive_change","fact_key":"1c89aa9d88","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2022-08-31T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-08-31","interim":false,"role":"Chairman of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Stavros Vizirgianakis was appointed as Chairman of the Board at Xtant Medical Holdings, Inc..","evidence_excerpt":"the Board elected Mr. Vizirgianakis as Chairman of the Board, effective upon completion of the First Closing, to replace Jeffrey Peters, who previously served as Chairman of the Board and intends not to stand for re-election at the Company’s next annual meeting of stockholders","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-22-024444","anchor_url":"https://secwatch.observer/filing/0001493152-22-024444#claim-1c89aa9d88","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315222024444/0001493152-22-024444-index.htm"},{"fact_type":"executive_change","fact_key":"a16427ff7f","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2022-08-24T23:59:59+00:00","payload":{"action":"replaced as Chairman","action_category":"role_change","departure_tone":"routine","effective_date":null,"interim":false,"role":"Chairman of the Board","role_category":"chair","successor_name":"Stavros Vizirgianakis","successor_named":true},"claim":"Jeffrey Peters changed role as Chairman of the Board at Xtant Medical Holdings, Inc..","evidence_excerpt":"to replace Jeffrey Peters, who is currently serving as Chairman of the Board and intends not to stand for re-election at the Company's next annual meeting of stockholders","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-22-023900","anchor_url":"https://secwatch.observer/filing/0001493152-22-023900#claim-a16427ff7f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315222023900/0001493152-22-023900-index.htm"},{"fact_type":"executive_change","fact_key":"82fea95cf3","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2022-05-02T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-06-01","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Scott C. Neils was appointed as Chief Financial Officer at Xtant Medical Holdings, Inc..","evidence_excerpt":"On April 27, 2022, the Board of Directors of Xtant Medical Holdings, Inc. (the “Company”) approved the appointment of Scott C. Neils as non-interim Chief Financial Officer, effective June 1, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-22-011719","anchor_url":"https://secwatch.observer/filing/0001493152-22-011719#claim-82fea95cf3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315222011719/0001493152-22-011719-index.htm"},{"fact_type":"executive_change","fact_key":"0ef49151ce","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2022-01-03T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-01-03","interim":true,"role":"Interim Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Scott Neils was appointed as Interim Chief Financial Officer at Xtant Medical Holdings, Inc..","evidence_excerpt":"announced the appointment of Scott Neils as Interim Chief Financial Officer","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-22-000042","anchor_url":"https://secwatch.observer/filing/0001493152-22-000042#claim-0ef49151ce","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315222000042/0001493152-22-000042-index.htm"},{"fact_type":"executive_change","fact_key":"ac04c04380","cik":1453593,"ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2022-01-03T23:59:59+00:00","payload":{"action":"terminated","action_category":"departure","departure_tone":"routine","effective_date":"2022-01-03","interim":false,"role":"Vice President, Finance and Chief Financial Officer","role_category":"cfo","successor_name":"Scott Neils","successor_named":true},"claim":"Greg Jensen was terminated as Vice President, Finance and Chief Financial Officer at Xtant Medical Holdings, Inc..","evidence_excerpt":"whose employment terminated effective as of January 3, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-22-000042","anchor_url":"https://secwatch.observer/filing/0001493152-22-000042#claim-ac04c04380","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315222000042/0001493152-22-000042-index.htm"}]}